208 related articles for article (PubMed ID: 8435897)
1. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
3. A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study.
Brue T; Lancranjan I; Louvet JP; Dewailly D; Roger P; Jaquet P
Fertil Steril; 1992 Jan; 57(1):74-80. PubMed ID: 1730334
[TBL] [Abstract][Full Text] [Related]
4. Long-acting injectable bromocriptine (Parlodel LAR) in the chronic treatment of prolactin-secreting macroadenomas.
Lengyel AM; Mussio W; Imamura P; Vieira JG; Lancranjan I
Fertil Steril; 1993 May; 59(5):980-7. PubMed ID: 8486199
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
6. Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections.
Paoletti AM; Cagnacci A; Mais V; Ajossa S; Guerriero S; Murgia C; Depau GF; Serra GG; Melis GB
Clin Exp Obstet Gynecol; 1994; 21(2):124-8. PubMed ID: 8070116
[TBL] [Abstract][Full Text] [Related]
7. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
8. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
Tyson D; Reggiardo D; Sklar C; David R
Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
[TBL] [Abstract][Full Text] [Related]
9. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
[TBL] [Abstract][Full Text] [Related]
10. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
11. [Short-term effect of delayed-action injectable bromocriptine in macroprolactinoma. French multicenter study].
Brue T; James-Deidier A; Louvet JP; Dewailly D; Roger P; Schlienger JL; Schaison G; Hartemann P; Jaquet P
Ann Endocrinol (Paris); 1991; 52(4):273-82. PubMed ID: 1818531
[TBL] [Abstract][Full Text] [Related]
12. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas.
Maraschini C; Moro M; Masala A; Toja P; Alagna S; Brunani A; Rovasio PP; Ginanni A; Lancranjan I; Cavagnini F
Acta Endocrinol (Copenh); 1991 Nov; 125(5):494-501. PubMed ID: 1759539
[TBL] [Abstract][Full Text] [Related]
13. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
14. Parlodel LAR in the treatment of macroprolactinomas.
Kocijancic A; Prezelj J; Vrhovec I; Lancranjan I
Acta Endocrinol (Copenh); 1990 Feb; 122(2):272-6. PubMed ID: 2316314
[TBL] [Abstract][Full Text] [Related]
15. Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients.
Jamrozik SI; Bennet AP; James-Deidier A; Tremollieres F; Saint-Martin F; Dumoulin S; Valat-Coustols M; de Glisezinski I; Tremoulet M; Manelfe C; Louvet JP
J Endocrinol Invest; 1996; 19(7):472-9. PubMed ID: 8884542
[TBL] [Abstract][Full Text] [Related]
16. [Long-acting and repeatable dose bromocriptine in the prolonged treatment of prolactinoma].
Pereira JL; García-Luna PP; Leal-Cerro A; Cortés A; Trujillo F; Villamil F; Vaquero F; Revuelta M; Astorga R
Med Clin (Barc); 1994 Jun; 103(2):59-64. PubMed ID: 8051973
[TBL] [Abstract][Full Text] [Related]
17. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
19. Long-acting repeatable bromocriptine in the treatment of patients with microprolactinoma intolerant or resistant to oral dopaminergics.
Espinós JJ; Rodríguez-Espinosa J; Webb SM; Calaf-Alsina J
Fertil Steril; 1994 Nov; 62(5):926-31. PubMed ID: 7926136
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]